Mifepristone is used for managing symptoms associated with Cushing's syndrome. It was first introduced by Danco Laboratories Llc in its drug Mifeprex on Sep 28, 2000. Another drug containing Mifepristone is Korlym. 4 different companies have introduced drugs containing Mifepristone.

Mifepristone Patents

Given below is the list of patents protecting Mifepristone, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Korlym	US10231983	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug 22, 2038	Corcept Therap
Korlym	US10314850	Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug 22, 2038	Corcept Therap
Korlym	US10780097	Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients	Aug 22, 2038	Corcept Therap
Korlym	US10195214	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun 19, 2037	Corcept Therap
Korlym	US10842800	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun 19, 2037	Corcept Therap
Korlym	US11969435	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun 19, 2037	Corcept Therap
Korlym	US12097210	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors	Jun 19, 2037	Corcept Therap
Korlym	US10151763	Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome	Jan 18, 2037	Corcept Therap
Korlym	US9829495	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug 15, 2036	Corcept Therap
Korlym	US10006924	Method for differentially diagnosing ACTH-dependent cushing's syndrome	Aug 12, 2036	Corcept Therap
Korlym	US10495650	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug 12, 2036	Corcept Therap
Korlym	US10166242	Optimizing mifepristone levels for Cushing's patients	Apr 20, 2036	Corcept Therap
Korlym	US10166243	Optimizing mifepristone levels for cushing'S patients	Apr 20, 2036	Corcept Therap
Korlym	US10660904	Optimizing mifepristone levels for cushing's patients	Apr 20, 2036	Corcept Therap
Korlym	US9943526	Optimizing mifepristone levels for cushing's patients	Apr 20, 2036	Corcept Therap
Korlym	US10500216	Optimizing mifepristone absorption	Mar 05, 2033	Corcept Therap
Korlym	US10842801	Optimizing mifepristone absorption	Nov 15, 2032	Corcept Therap
Korlym	US8921348	Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists	Aug 27, 2028	Corcept Therap

Add above patents to watchlist

Mifepristone's Family Patents

Unlock Global Patents

Mifepristone Generic API Manufacturers

Several generic applications have been filed for Mifepristone. The first generic version for Mifepristone was by Genbiopro Inc and was approved on Apr 11, 2019. And the latest generic version is by Teva Pharmaceuticals Usa Inc and was approved on Aug 3, 2020.

Given below is the list of companies who have filed for Mifepristone generic, along with the locations of their manufacturing plants worldwide.